Publications by authors named "Knut Selsas"
Article Synopsis
- * The NEOLETRIB trial specifically assesses the effectiveness of combining letrozole (an aromatase inhibitor) and ribociclib (a CDK4/6-inhibitor) in ER-positive, HER2-negative luminal A/B breast cancer patients.
- * The study includes comprehensive molecular biology techniques, such as single-cell RNA sequencing, to analyze tumor responses and make better treatment decisions, with the aim of enhancing patient selection for this combination therapy.
Article Synopsis
- The study compares the effectiveness of two cancer drugs, letrozole and exemestane, in lowering estrogen levels for postmenopausal women with ER-positive breast cancer.
- Patients participated in an intra-patient cross-over design, first receiving one drug followed by the other, while serum estrogen and drug levels were measured using a sensitive laboratory method.
- Results showed that letrozole was more effective at reducing estrogen levels compared to exemestane, with significant decreases observed after treatment with either drug.
Purpose: The aromatase inactivator exemestane may cause clinical disease stabilization following progression on non-steroidal aromatase inhibitors like letrozole in patients with metastatic breast cancer, indicating that additional therapeutic effects, not necessarily related to estrogen-suppression, may be involved in this well-known "lack of cross-resistance".
Methods: Postmenopausal women with ER positive, HER-2 negative, locally advanced breast cancer were enrolled in the NEOLETEXE-trial and randomized to sequential treatment starting with either letrozole (2.5 mg o.